NF1 and pulmonary arterial hypertension: Long-term outcomes in NF1-associated PAH remain poor in reported cohorts, underscoring the importance of close monitoring, consideration of alternative therapeutic targets (e.g., Ras-MAPK inhibition), and early referral to a specialized PH center.